Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moon Haeng Hur

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Gut and Liver|July 17, 2025
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver DiseaseYunmi Ko, Moon Haeng Hur, Youngsu Park, et al.
Liver Cancer|June 24, 2026
Adverse Event Monitoring with Imaging: Prognostic Significance in Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular CarcinomaJeayeon Park, Dong Ho Lee, Yunmi Ko, et al.
Life Sciences|March 2, 2023
Chemogenetic stimulation of the parasympathetic nervous system lowers hepatic lipid accumulation and inflammation in a nonalcoholic steatohepatitis mouse modelMoon Haeng Hur, Woojin Song, Deok-Hyeon Cheon, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 17, 2024
Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort studyMin Kyung Park, Moon Haeng Hur, Hye-Sung Moon, et al.
JHEP Reports : Innovation in Hepatology|July 8, 2024
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosisHyunjae Shin, Won-Mook Choi, Seung Up Kim, et al.
Clinical and Molecular Hepatology|November 25, 2025
Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysisJuhee Ahn, Moon Haeng Hur, Hyunjae Shin, et al.
Clinical and Molecular Hepatology|May 31, 2023
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosisMoon Haeng Hur, Yuri Cho, Do Young Kim, et al.
BMC Gastroenterology|March 26, 2022
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysisNa Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 11, 2025
Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosisYunmi Ko, Byeong Geun Song, Hyunjae Shin, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 22, 2025
Correction: Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosisYunmi Ko, Byeong Geun Song, Hyunjae Shin, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Gut and Liver|July 17, 2025
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver DiseaseYunmi Ko, Moon Haeng Hur, Youngsu Park, et al.
Liver Cancer|June 24, 2026
Adverse Event Monitoring with Imaging: Prognostic Significance in Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular CarcinomaJeayeon Park, Dong Ho Lee, Yunmi Ko, et al.
Life Sciences|March 2, 2023
Chemogenetic stimulation of the parasympathetic nervous system lowers hepatic lipid accumulation and inflammation in a nonalcoholic steatohepatitis mouse modelMoon Haeng Hur, Woojin Song, Deok-Hyeon Cheon, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 17, 2024
Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort studyMin Kyung Park, Moon Haeng Hur, Hye-Sung Moon, et al.
JHEP Reports : Innovation in Hepatology|July 8, 2024
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosisHyunjae Shin, Won-Mook Choi, Seung Up Kim, et al.
Clinical and Molecular Hepatology|November 25, 2025
Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysisJuhee Ahn, Moon Haeng Hur, Hyunjae Shin, et al.
Clinical and Molecular Hepatology|May 31, 2023
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosisMoon Haeng Hur, Yuri Cho, Do Young Kim, et al.
BMC Gastroenterology|March 26, 2022
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysisNa Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 11, 2025
Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosisYunmi Ko, Byeong Geun Song, Hyunjae Shin, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 22, 2025
Correction: Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosisYunmi Ko, Byeong Geun Song, Hyunjae Shin, et al.
Pageof 5